The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
      QxMD      Google Scholar   
Citation:
Neuro-oncol vol 9 (1) 29-38
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
559  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
               
Primary Study
N047D
Secondary Studies:
Phases:
N/A
Keywords:
end points, glioblastoma multiforme, phase II clinical trials